Bharathiraja Subramaniyan
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunity, Innate | 2 | 2025 | 232 | 1.360 |
Why?
|
| Cleft Lip | 2 | 2024 | 8 | 1.090 |
Why?
|
| Cleft Palate | 2 | 2024 | 15 | 1.080 |
Why?
|
| Photochemotherapy | 3 | 2025 | 42 | 0.990 |
Why?
|
| Receptors, Steroid | 1 | 2025 | 26 | 0.890 |
Why?
|
| Language Therapy | 1 | 2024 | 1 | 0.880 |
Why?
|
| Speech Therapy | 1 | 2024 | 3 | 0.880 |
Why?
|
| Speech-Language Pathology | 1 | 2024 | 3 | 0.870 |
Why?
|
| Bronchi | 2 | 2021 | 38 | 0.860 |
Why?
|
| Professional Role | 1 | 2024 | 46 | 0.850 |
Why?
|
| Antiviral Agents | 1 | 2025 | 114 | 0.850 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2020 | 54 | 0.770 |
Why?
|
| Paclitaxel | 2 | 2020 | 200 | 0.730 |
Why?
|
| Respiratory Mucosa | 1 | 2021 | 68 | 0.670 |
Why?
|
| Prodrugs | 2 | 2020 | 30 | 0.670 |
Why?
|
| Breast Neoplasms | 2 | 2025 | 483 | 0.580 |
Why?
|
| Receptor, Notch3 | 3 | 2022 | 15 | 0.400 |
Why?
|
| Epithelial Cells | 3 | 2023 | 266 | 0.360 |
Why?
|
| Humans | 12 | 2025 | 28909 | 0.330 |
Why?
|
| Lung | 2 | 2023 | 384 | 0.310 |
Why?
|
| Cell Differentiation | 2 | 2021 | 427 | 0.290 |
Why?
|
| Animals | 6 | 2025 | 10707 | 0.270 |
Why?
|
| Erbium | 1 | 2025 | 1 | 0.230 |
Why?
|
| Ferrocyanides | 1 | 2025 | 3 | 0.230 |
Why?
|
| Signal Transduction | 5 | 2025 | 1469 | 0.230 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2025 | 28 | 0.230 |
Why?
|
| Durapatite | 1 | 2025 | 15 | 0.230 |
Why?
|
| Tetraspanins | 1 | 2025 | 54 | 0.230 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2025 | 65 | 0.220 |
Why?
|
| Capillary Permeability | 1 | 2025 | 56 | 0.220 |
Why?
|
| Virus Replication | 1 | 2025 | 66 | 0.220 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 48 | 0.220 |
Why?
|
| Developing Countries | 1 | 2024 | 49 | 0.210 |
Why?
|
| Cholesterol | 1 | 2025 | 203 | 0.210 |
Why?
|
| Deubiquitinating Enzymes | 1 | 2023 | 6 | 0.210 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 68 | 0.200 |
Why?
|
| Cell Membrane | 1 | 2025 | 268 | 0.200 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2023 | 14 | 0.200 |
Why?
|
| Papio | 1 | 2023 | 81 | 0.190 |
Why?
|
| Biological Phenomena | 1 | 2022 | 4 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 409 | 0.190 |
Why?
|
| Lung Diseases | 1 | 2022 | 43 | 0.180 |
Why?
|
| Endothelial Cells | 1 | 2025 | 373 | 0.180 |
Why?
|
| Cells, Cultured | 2 | 2021 | 1022 | 0.180 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 53 | 0.170 |
Why?
|
| Goblet Cells | 1 | 2021 | 15 | 0.170 |
Why?
|
| Cell Death | 1 | 2021 | 119 | 0.170 |
Why?
|
| Interferons | 1 | 2021 | 70 | 0.170 |
Why?
|
| Nanoparticles | 1 | 2025 | 291 | 0.170 |
Why?
|
| Smoke | 1 | 2021 | 37 | 0.170 |
Why?
|
| Repressor Proteins | 1 | 2021 | 119 | 0.170 |
Why?
|
| Cellular Senescence | 1 | 2021 | 141 | 0.160 |
Why?
|
| Rats, Inbred F344 | 1 | 2020 | 174 | 0.160 |
Why?
|
| Cigarette Smoking | 1 | 2021 | 85 | 0.150 |
Why?
|
| Female | 5 | 2025 | 15650 | 0.150 |
Why?
|
| Cytokines | 1 | 2021 | 452 | 0.150 |
Why?
|
| Tobacco Products | 1 | 2021 | 209 | 0.130 |
Why?
|
| Models, Biological | 1 | 2019 | 469 | 0.130 |
Why?
|
| Inflammation | 1 | 2021 | 668 | 0.130 |
Why?
|
| Rats | 1 | 2020 | 1590 | 0.120 |
Why?
|
| Aged | 2 | 2021 | 5604 | 0.110 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 1509 | 0.110 |
Why?
|
| Aging | 1 | 2021 | 1019 | 0.100 |
Why?
|
| Male | 3 | 2024 | 13947 | 0.090 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 1351 | 0.070 |
Why?
|
| Time Factors | 2 | 2021 | 1615 | 0.060 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2025 | 16 | 0.060 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2025 | 25 | 0.060 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2025 | 33 | 0.060 |
Why?
|
| Simvastatin | 1 | 2025 | 24 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2025 | 77 | 0.060 |
Why?
|
| Esthetics | 1 | 2024 | 5 | 0.050 |
Why?
|
| Palatal Obturators | 1 | 2024 | 3 | 0.050 |
Why?
|
| Alveolar Process | 1 | 2024 | 11 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2024 | 46 | 0.050 |
Why?
|
| Nose | 1 | 2024 | 24 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2025 | 128 | 0.050 |
Why?
|
| India | 1 | 2024 | 147 | 0.050 |
Why?
|
| Cell Survival | 1 | 2025 | 419 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2025 | 292 | 0.050 |
Why?
|
| Receptors, Notch | 1 | 2022 | 44 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2025 | 876 | 0.050 |
Why?
|
| Mammals | 1 | 2022 | 48 | 0.050 |
Why?
|
| Air | 1 | 2021 | 23 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2021 | 25 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 28 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2024 | 916 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 1026 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 198 | 0.040 |
Why?
|
| Smokers | 1 | 2021 | 129 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 232 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 739 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2021 | 825 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 634 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 122 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2024 | 2426 | 0.030 |
Why?
|
| Middle Aged | 1 | 2021 | 7419 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 4811 | 0.020 |
Why?
|
| Adult | 1 | 2021 | 8037 | 0.020 |
Why?
|